Abstract
Following a washout period, one hundred six patients with osteoarthritis were randomly assigned single daily doses of either 1,000 mg of nabumetone or placebo given at bedtime as part of a six-week, controlled, double-blind study. Forty-seven patients received nabumetone, whereas 48 patients were given placebo. Treatment groups were comparable for demographic characteristics, baseline efficacy assessments, and diagnostic criteria for osteoarthritis. Nabumetone-treated patients had absolute improvement, as well as relative improvement in comparison with placebo, both clinically and statistically. There were no clinical or statistical differences in safety variables between the two groups. When given once daily at bedtime, nabumetone was effective and had a good safety profile in patients with osteoarthritis.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
